330 related articles for article (PubMed ID: 35844495)
1. Increased Tumor Intrinsic Growth Potential and Decreased Immune Function Orchestrate the Progression of Lung Adenocarcinoma.
Zhao Y; Shang J; Gao J; Han H; Gao Z; Yan Y; Zheng Q; Ye T; Fu F; Deng C; Ma Z; Zhang Y; Zheng D; Zheng S; Li Y; Cao Z; Shi L; Chen H
Front Immunol; 2022; 13():921761. PubMed ID: 35844495
[TBL] [Abstract][Full Text] [Related]
2. Evolution of lung adenocarcinoma from preneoplasia to invasive adenocarcinoma.
Zhu J; Wang W; Xiong Y; Xu S; Chen J; Wen M; Zhao Y; Lei J; Jiang T
Cancer Med; 2023 Mar; 12(5):5545-5557. PubMed ID: 36325966
[TBL] [Abstract][Full Text] [Related]
3. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Analysis and Reinforcement Learning of Hypoxic Genes Based on Four Machine Learning Algorithms for Estimating the Immune Landscape, Clinical Outcomes, and Therapeutic Implications in Patients With Lung Adenocarcinoma.
Sun Z; Zeng Y; Yuan T; Chen X; Wang H; Ma X
Front Immunol; 2022; 13():906889. PubMed ID: 35757722
[TBL] [Abstract][Full Text] [Related]
5. Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma.
Shen M; Jiang K; Sui Y; Xu Z; Cui H; Wang Y; Zhang H; Xu Z; Xu W; Ding Q; Chen Y
Lung Cancer; 2021 Oct; 160():84-91. PubMed ID: 34479175
[TBL] [Abstract][Full Text] [Related]
6. Subtype classification based on t cell proliferation-related regulator genes and risk model for predicting outcomes of lung adenocarcinoma.
Yang Q; Zhu W; Gong H
Front Immunol; 2023; 14():1148483. PubMed ID: 37077919
[TBL] [Abstract][Full Text] [Related]
7. ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma.
Zhang W; Shang X; Liu N; Ma X; Yang R; Xia H; Zhang Y; Zheng Q; Wang X; Liu Y
BMC Pulm Med; 2022 Dec; 22(1):483. PubMed ID: 36539782
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
9. HMMR associates with immune infiltrates and acts as a prognostic biomaker in lung adenocarcinoma.
Ma X; Xie M; Xue Z; Yao J; Wang Y; Xue X; Wang J
Comput Biol Med; 2022 Dec; 151(Pt A):106213. PubMed ID: 36306573
[TBL] [Abstract][Full Text] [Related]
10. [Comprehensive Analysis of the Relationship between m6A Methylation Patterns and Immune Microenvironment in Lung Adenocarcinoma].
Ke J; Cui J; Yang X; Du X; Ma B; Yu L
Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):311-322. PubMed ID: 35599007
[TBL] [Abstract][Full Text] [Related]
11. Investigating subtypes of lung adenocarcinoma by oxidative stress and immunotherapy related genes.
Duan G; Huang C; Zhao J; Zhang Y; Zhao W; Dai H
Sci Rep; 2023 Nov; 13(1):20930. PubMed ID: 38017020
[TBL] [Abstract][Full Text] [Related]
12. Protein phosphatase 1 regulatory subunit 3G (PPP1R3G) correlates with poor prognosis and immune infiltration in lung adenocarcinoma.
Zhuo X; Chen L; Lai Z; Liu J; Li S; Hu A; Lin Y
Bioengineered; 2021 Dec; 12(1):8336-8346. PubMed ID: 34592886
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of CXCR family members in lung adenocarcinoma with prognostic values.
Hu LT; Deng WJ; Chu ZS; Sun L; Zhang CB; Lu SZ; Weng JR; Ren QS; Dong XY; Li WD; Li XB; Du YT; Li Y; Wang WQ
BMC Pulm Med; 2022 Jun; 22(1):259. PubMed ID: 35768814
[TBL] [Abstract][Full Text] [Related]
14. Genomic landscape and tumor mutational features of resected preinvasive to invasive lung adenocarcinoma.
Lin Y; Li D; Hui H; Miao H; Luo M; Roy B; Chen B; Zhang W; Shao D; Ma D; Jie Y; Qiu F; Li H; Jiang B
Front Oncol; 2024; 14():1389618. PubMed ID: 38803537
[TBL] [Abstract][Full Text] [Related]
15. An Investigation of the Immune Microenvironment and Genome during Lung Adenocarcinoma Development.
Wang Q; Xie B; Sun J; Li Z; Xiao D; Tao Y; She X
J Cancer; 2024; 15(6):1687-1700. PubMed ID: 38370388
[No Abstract] [Full Text] [Related]
16. Integrated whole-exome and bulk transcriptome sequencing delineates the dynamic evolution from preneoplasia to invasive lung adenocarcinoma featured with ground-glass nodules.
Zhou D; Li YQ; Liu QX; Deng XF; Chen L; Li MY; Zhang J; Lu X; Zheng H; Dai JG
Cancer Med; 2024 Jun; 13(11):e7383. PubMed ID: 38864483
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel gene expression signature associated with overall survival in patients with lung adenocarcinoma: A comprehensive analysis based on TCGA and GEO databases.
Zhao J; Guo C; Ma Z; Liu H; Yang C; Li S
Lung Cancer; 2020 Nov; 149():90-96. PubMed ID: 33002836
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
[TBL] [Abstract][Full Text] [Related]
19. NRAS expression is associated with prognosis and tumor immune microenvironment in lung adenocarcinoma.
Yan Y; Gao Z; Han H; Zhao Y; Zhang Y; Ma X; Chen H
J Cancer Res Clin Oncol; 2022 Mar; 148(3):565-575. PubMed ID: 34746975
[TBL] [Abstract][Full Text] [Related]
20. Differences of molecular events driving pathological and radiological progression of lung adenocarcinoma.
Shang J; Jiang H; Zhao Y; Lai J; Shi L; Yang J; Chen H; Zheng Y
EBioMedicine; 2023 Aug; 94():104728. PubMed ID: 37506543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
